Could a new pill for schizophrenia pass its first human test?
Disease control
Ongoing
This early-stage trial evaluates an experimental oral drug called VV119, which is being developed for schizophrenia. The study enrolls healthy volunteers to receive a single dose of VV119 or a placebo, with some participants taking it with food to see if meals affect how the drug…
Phase: PHASE1 • Sponsor: Vigonvita Life Sciences • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC